Hepatitis C
Authors: Janice H. Jou, Andrew J. Muir
Journal: Annals of Internal Medicine (2008)

In the Clinic3 June 2008Hepatitis CChristine Laine, MD, MPH, David R. Goldman, MD, Janice H. Jou, MD, and Andrew J. Muir, MDChristine Laine, MD, MPH, David R. Goldman, MD, Janice H. Jou, MD, and Andrew J. Muir, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-148-11-200806030-01006 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Editor's Note: This issue of In the Clinic has been updated.Chronic hepatitis C virus (HCV) infection is the most common blood-borne infection in the United States, with an estimated overall prevalence of 3.2 million persons (1.3%) and prevalence peaks between age 40 to 49 years (1). The worldwide prevalence of HCV infection is even higher at 2.0%, corresponding to 140 million persons (2).In terms of complications, cirrhosis due to HCV disease is the most frequent indication for liver transplantation in the United States (3), and the overall incidence of hepatocellular carcinoma, a complication of HCV cirrhosis, continues to ...References1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14. [PMID: 16702586] Google Scholar2. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis. 2006; 10:697-715. [PMID: 17164113] Google Scholar3. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002. Hepatology. 2002;36:S3-20. [PMID: 12407572] Google Scholar4. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817-23. [PMID: 14623619] Google Scholar5. Hwang LY, Kramer JR, Troisi C, et al. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. Hepatology. 2006;44:341-51. [PMID: 16871571] Google Scholar6. Lanphear BP, Linnemann CC Jr, Cannon CG, et al. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol. 1994;15:745-50. [PMID: 7534324] Google Scholar7. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3-10. [PMID: 12085342] Google Scholar8. Macedo de Oliveira A, White KL, Leschinsky DP, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med. 2005;142:898-902. [PMID: 15941696] Google Scholar9. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36:S99-105. [PMID: 12407582] Google Scholar10. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002;36:S106-13. [PMID: 12407583] Google Scholar11. Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health. 2000;77:369-82. [PMID: 10976611] Google Scholar12. Amsterdam Cohort. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007;102:1454-62. [PMID: 17697278] Google Scholar13. Shapiro CN. Transmission of hepatitis viruses [Editorial]. Ann Intern Med. 1994;120:82-4. [PMID: 8250462] Google Scholar14. Lock G, Dirscherl M, Obermeier F, et al. Hepatitis C - contamination of toothbrushes: myth or reality? J Viral Hepat. 2006;13:571-3. [PMID: 16907842] Google Scholar15. Sawayama Y, Hayashi J, Kakuda K, et al. Hepatitis C virus infection in institutionalized psychiatric patients: possible role of transmission by razor sharing. Dig Dis Sci. 2000;45:351-6. [PMID: 10711450] Google Scholar16. Siegel JD, Rhinehart E, Jackson, M, et al., and the Healthcare Infection Control Practices Advisory Committee. Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 2007, June 2007. Accessed at www.cdc.gov/ncidod/dhqp/pdf/guidelines/Isolation2007.pdf on 14 April 2008. Google Scholar17. U.S. Preventive Services Task Force. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004; 140:465-79. [PMID: 15023713] Google Scholar18. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med. 2004;141:715-7. [PMID: 15520428] Google Scholar19. Vrielink H, Reesink HW, van den Burg PJ, et al. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients. Transfusion. 1997;37:845-9. [PMID: 9280331] Google Scholar20. Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol. 2005;42: 266. [PMID: 15664254] Google Scholar21. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore). 2000;79:47-56. [PMID: 10670409] Google Scholar22. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47:1-39. [PMID: 9790221] Google Scholar23. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol. 1999;31 Suppl 1:54-60. [PMID: 10622561] Google Scholar24. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31 Suppl 1:9-16. [PMID: 10622554] Google Scholar25. Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805-9. [PMID: 9731576] Google Scholar26. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther. 2005;12:133-41. [PMID: 15767831] Google Scholar27. Rambaldi A, Jacobs BP, Iaquinto G, et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases—a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol. 2005;100:2583-91. [PMID: 16279916] Google Scholar28. Verma S, Thuluvath PJ. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol. 2007;5:408-16. [PMID: 17222587] Google Scholar29. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol. 2007;41: 761-72. [PMID: 17700425] Google Scholar30. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-7. [PMID: 11170959] Google Scholar31. ANRS HCO2 RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-48. [PMID: 15598915] Google Scholar32. Kim AI, Dorn A, Bouajram R, et al. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis. HIV Med. 2007;8:312-21. [PMID: 17561878] Google Scholar33. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52. [PMID: 11439948] Google Scholar34. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140:346-55. [PMID: 14996676] Google Scholar35. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975-82. [PMID: 12324553] Google Scholar36. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358: 958-65. [PMID: 11583749] Google Scholar37. Virahep-C Study Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-7. [PMID: 16890601] Google Scholar38. Jakiche R, Borrego ME, Raisch DW, et al. The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses. Am J Med Sci. 2007;333: 26-34. [PMID: 17220691] Google Scholar39. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 1997; 46:1-42. [PMID: 9427216] Google Scholar40. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1-24. [PMID: 9132580] Google Scholar41. Kelleher TB, Afdhal N. Maintenance therapy for chronic hepatitis C. Curr Gastroenterol Rep. 2005;7:50-3. [PMID: 15701299] Google Scholar42. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007;46:640-8. [PMID: 17879366] Google Scholar43. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273-9. [PMID: 12395340] Google Scholar44. PROACTIVE Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004;40: 1450-8. [PMID: 15565613] Google Scholar45. U.S. Food and Drug Administration. FDA Public Health Advisory: Erythropoiesis-Stimulating Agents (ESAs). Accessed at www.fda.gov/cder/drug/advisory/RHE 2007.htm on 14 April 2008. Google Scholar46. TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007; 357:2227-36. [PMID: 18046027] Google Scholar47. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-52. [PMID: 12939591] Google Scholar48. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis. 2008;46:78-84. [PMID: 18171217] Google Scholar49. Dienstag JL, McHutchison JG. American Gastro-enterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-64; quiz 214-7. [PMID: 16401486] Google Scholar50. AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-32. [PMID: 15880505] Google Scholar51. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-22. [PMID: 15042359] Google Scholar52. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36. [PMID: 16250051] Google Scholar53. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-71. [PMID: 15057920] Google Scholar54. U.S. Department of Veterans Affairs. The United States Department for Veterans Affairs Hepatitis C Testing and Prevention Counseling Guidelines for VA Health Care Practitioners. Accessed at www.hepatitis .va.gov on 14 April 2008 Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMicrofluidic barcode assay for antibody-based confirmatory diagnosticsDirect quantitative analysis of HCV RNA by atomic force microscopy without labeling or amplificationTelaprevir for retreatment of HCV infection: review of the REALIZE trialTelaprevir for the treatment of chronic hepatitis C infectionPreoperative Preparation and InstructionsHepatitis C in Haematological PatientsHigh antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infectionMR Imaging of Liver Fibrosis: Current State of the Art 3 June 2008Volume 148, Issue 11Page: ITC6-1KeywordsBiopsyCirrhosisDrugsHepatitis CInfectious diseasesLiverLiver diseasesLiver fibrosisLiver transplantation ePublished: 3 June 2008 Issue Published: 3 June 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...